BRD2 bromodomain 1 (65-187 aa) (GST-tagged), human recombinant protein
Human recombinant BRD2 bromodomain 1 (65-187 aa) (GST-tagged)
|Calculated MW||42.4 kDa (65-187 aa + NT GST Tag)|
|Other Names||RING3; RNF3; Bromodomain containing 4|
|Storage||-80°C; 50 mM Tris, pH 7.5, containing 500 mM sodium chloride, 5% glycerol, and 5 mM β-mercaptoethanol.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The acetylation of histone lysine residues plays a crucial role in the epigenetic regulation of gene transcription. A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histones. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. These domains function in the linking of protein complexes to acetylated nucleosomes, thereby controlling chromatin structure and gene expression. Thus, bromodomains serve as “readers” of histone acetylation marks regulating the transcription of target promoters. The BET family of proteins, defined by tandem Bromodomains and an Extra Terminal domain, include BRD2, BRD3, BRD4, and BRDT. The BET proteins play a key role in many cellular processes, including inflammatory gene expression, mitosis, and viral/host interactions. The isolated individual or tandem bromodomains of BRD2 and BRD4 have been shown to bind acetylated histone tails, serving to couple histone acetylation marks to the transcriptional regulation of target promoters. Small molecule inhibitors of these interactions hold promise as useful therapeutics for human disease. This protein can be used for the study of bromodomain binding assays, screening inhibitors, and selectivity profiling.
Beck S.,et al.DNA Seq. 2:203-210(1992).
Thorpe K.L.,et al.Immunogenetics 44:391-396(1996).
Nomura N.,et al.Submitted (JUL-1997) to the EMBL/GenBank/DDBJ databases.
Bechtel S.,et al.BMC Genomics 8:399-399(2007).
Mungall A.J.,et al.Nature 425:805-811(2003).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.